KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2025)

Historic Other Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Q3 2025 value amounting to $1.0 million.

  • Recursion Pharmaceuticals' Other Non-Current Liabilities fell 6568.86% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 6568.86%. This contributed to the annual value of $4.7 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Other Non-Current Liabilities is $1.0 million, which was down 6568.86% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Other Non-Current Liabilities registered a high of $4.8 million during Q1 2025, and its lowest value of $1.0 million during Q3 2025.